Effects of MDMA on blood glucose levels and brain glucose metabolism

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 6, 2007, Pages 916-925

  Soto Montenegro, M L ^a   Vaquero, J J ^a   Arango, C ^a   Ricaurte, G ^b   Garcia Barreno P ^a   Desco, M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain metabolism; FDG; MDMA; PET

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUDITORY CORTEX; BODY TEMPERATURE; BRAIN REGION; BRAIN STEM; CAUDATE NUCLEUS; CEREBELLUM; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; IMAGING SYSTEM; NEUROTOXICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RAT; RECTUM TEMPERATURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSENSORY CORTEX; STATISTICAL SIGNIFICANCE; SUPERIOR COLLICULUS; THALAMUS; VISUAL CORTEX;

ADRENERGIC UPTAKE INHIBITORS; AMYGDALA; ANIMALS; AUDITORY CORTEX; BLOOD GLUCOSE; BRAIN; CEREBELLUM; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HIPPOCAMPUS; HYPOGLYCEMIA; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; RATS;

EID: 34248994276     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0262-8     Document Type: Article

References (55)

1. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 1996;73(1-2):103-7.
2. Cole JC, Sumnall HR. Altered states: the clinical effects of ecstasy. Pharmacol Ther 2003;98(1):35-58.
3. Schmidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 1987;36(23):4095-102.
4. Stone DM, Stahl DC, Hanson GR, Gibb JW. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 1986;128(1-2):41-8.
5. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001;39(1):32-41.
6. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 1995;119(3):247-60.
7. Obradovic T, Imel KM, White SR. Methylenedioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine. Neuroscience 1996;74(2):469-81.
8. White SR, Obradovic T, Imel KM, Wheaton MJ. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 1996;49(5):455-79.
9. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 1998;51(6):1532-7.
10. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998;352(9138):1433-7.
11. Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB. 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 1989;249(3):713-20.
12. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4- methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999;19(12):5096-107.
13. Ricaurte GA, McCann UD, Szabo Z, Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett 2000;112-113:143-6.
14. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, et al. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 2004;29:1270-81.
15. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 2003;55(3):463-508.
16. De Win MM, Reneman L, Reitsma JB, Den Heeten GJ, Booij J, Van Den Brink W. Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 2004;173:376-82.
17. Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, et al. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 2006 Jan 25; [Epub ahead of print].
18. Li AA, Marek GJ, Vosmer G, Seiden LS. Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of MDMA on schedule-controlled behavior of rats. Pharmacol Biochem Behav 1989;33(3):641-8.
19. Wilkerson G, London ED. Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat. Neuropharmacology 1989;28(10):1129-38.
20. Frederick DL, Paule MG. Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev 1997;21(1):67-78.
21. 15O]-PET in healthy humans. Neuropsychopharmacology 2000;23(4):388-95.
22. Holland J. Positron emission tomography findings in heavy users of MDMA. Lancet 1999;353(9152):592-3.
23. Hurley RA, Reneman L, Taber KH. Ecstasy in the brain: a model for neuroimaging. J Neuropsychiatry Clin Neurosci 2002;14(2):125-9.
24. Jarkas N, McConathy J, Voll RJ, Goodman MM. Synthesis, in vitro characterization, and radiolabeling of N,N-dimethyl-2-(2′-amino-4′- substituted-phenylthio)benzylamines: potential candidates as selective serotonin transporter radioligands. J Med Chem 2005;48(13):4254-65.
25. 18F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl) thio]N,N-dimethyl-benzenmethanamine). J Med Chem 2002;45(21):4716-23.
26. Buchert, R, Obrocki J, Thomasius R, Vaterlein O, Petersen K, Jenicke L, et al. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl Med Commun 2001;22(8):889-97.
27. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998;37(7):919-26.
28. Soto-Montenegro M, Vaquero J, Molins A, Reig S, Desco M. FDG-PET studies of the effect of MDMA in rat brain. In: 10th Annual Meeting of the Organization for Human Brain Mapping. Hungary: Budapest; 2004.
29. Siegel S, Vaquero JJ, Aloj L, Seidel J, Gandler WR, Green MV. Initial results from a PET/planar small animal imaging system. IEEE Trans Nucl Sci 1999;46(3):571-575.
30. López Herráiz J, España S, Udías JM, Vaquero JJ, Seidel J, Desco M. Full 3D-OSEM reconstruction with compressed response of the system. Book of Abstracts of 2004 IEEE Nuclear Science Symposium and Medical Imaging Conference 2004:163.
31. Jagoda EM, Vaquero JJ, Seidel J, Green MV, Eckelman WC. Experiment assessment of mass effects in the rat: implications for small animal PET imaging. Nucl Med Biol 2004;31(6):771-9.
32. Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 1999;175:186-8.
33. Paxinos G, Watson C. The rat brain in stereotaxic coordinates, 4th ed. San Diego, CA: Academic Press; 1998; p 474.
34. Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 1995;115(7):1281-9.
35. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F. Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav 1999;64(1):29-34.
36. Vincent-Viry M, Deshayes S, Mothe O, Siest G, Galteau MM. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results. J Pharm Pharmacol 1988;40(10):695-700.
37. Boobis AR, Seddon CE, Davies DS. Bufuralol 1′-hydroxylase activity of the rat. Strain differences and the effects of inhibitors. Biochem Pharmacol 1986;35(17):2961-5.
38. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994;47(7):1151-6.
39. McCann UD, Slate SO, Ricaurte GA. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). Drug Saf 1996;15(2):107-15.
40. Parrott AC. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 2001;16(8):557-77.
41. Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998;18(13):5086-94.
42. Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 1994;177(1-2):111-5.
43. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 2004;26(2):137-44.
44. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340(8816):384-7.
45. Heffron JJ. Malignant hyperthermia: biochemical aspects of the acute episode. Br J Anaesth 1988;60(3):274-8.
46. Hall GM, Lucke JN, Lovell R, Lister D. Porcine malignant hyperthermia. VII: hepatic metabolism. Br J Anaesth 1980;52(1):11-7.
47. Andreu V, Mas A, Bruguera M, Salmeron JM, Moreno V, Nogue S, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998;29(3):394-7.
48. Montgomery H, Myerson S. 3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") and associated hypoglycemia. Am J Emerg Med 1997;15(2):218.
49. Lange-Brock N, Berg T, Muller AR, Fliege H, Neuhaus P, Wiedenmann B, et al. Acute liver failure following the use of ecstasy (MDMA). Z Gastroenterol 2002;40(8):581-6.
50. Vollenweider FX, Liechti ME, Gamma A, Greer G, Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. J Psychoact Drugs 2002;34(2):171-84.
51. McCulloch J, Savaki HE, Jehle J, Sokoloff L. Local cerebral glucose utilization in hypothermic and hyperthermic rats. J Neurochem 1982;39(1):255-8.
52. Nunneley SA, Martin CC, Slauson JW, Hearon CM, Nickerson LD, Mason PA. Changes in regional cerebral metabolism during systemic hyperthermia in humans. J Appl Physiol 2002;92(2):846-51.
53. Ricaurte GA, McCann UD. Recognition and management of complications of new recreational drug use. Lancet 2005;365(9477):2137-45.
54. Carlsson M, Svensson K, Eriksson E, Carlsson A. Rat brain serotonin: biochemical and functional evidence for a sex difference. J Neural Transm 1985;63(3-4):297-313.
55. Palenicek T, Votava M, Bubenikova V, Horacek J. Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol Behav 2005;86(4):546-53.